Clinical investigation of the effects of pioglitazone on the improvement of insulin resistance and blood pressure in Type 2-diabetic patients undergoing hemodialysis

被引:0
作者
Abe, M. [1 ]
Okada, K. [1 ]
Kikuchi, F. [2 ]
Matsumoto, K. [1 ]
机构
[1] Nihon Univ, Sch Med, Div Nephrol Hypertens & Endocrinol, Dept Med,Itabashi Ku, Tokyo 1738610, Japan
[2] Yamato Hosp, Dept Nephrol & Blood Purificat, Tokyo, Japan
关键词
insulin resistance; pioglitazone; hemodialysis; Type; 2; diabetes; hypertension;
D O I
暂无
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Aims: Type 2 diabetes is characterized by a combination of insulin resistance, dyslipidemia, and increased blood pressure. In this study, we evaluated the clinical efficacy of pioglitazone in the treatment of diabetic patients with hypertension undergoing hemodialysis (HD). Methods: An open-label, randomized study was performed using 40 subjects assigned to two groups: one group (pioglitaizone group) was administered an add-on pioglitazone therapy (fixed close, 30 mg) Plus conventional oral antidiabetic agents, and the other group (control group) was administered conventional oral agents alone. The treatment efficacy was determined by monitoring the glycemic control and insulin resistance, which were assessed based oil the homeostasis model assessment for insulin resistance (HOMA-IR). The safety of and tolerance to the drug were determined by monitoring clinical and laboratory parameters, Results: Pioglilazone was effective in reducing the plasma glucose and hemoglobin A(1c) levels from the baseline Values, beginning at 4 weeks of treatment. It was also effective in reducing the triglyceride levels. The HOMA-IR decreased significantly in the pioglitazone group, and this decrease was maintained until the last measurement, which was at 24 weeks. The systolic and diastolic blood pressure values were statistically lower in the pioglitazone group than ill the control group. No serious adverse effects were observed in any of the patients. Conclusions: Pioglitazone is safe and effective for the treatment of Type 2-diabetic patients Undergoing HD therapy. A daily dose of 30 mg pioglitazone is sufficient for treating HD patients, regardless of whether or not they are obese. Furthermore, pioglitazone reduced the systolic and diastolic blood pressure in our patients, and this effect requires further investigation.
引用
收藏
页码:220 / 228
页数:9
相关论文
共 46 条
[1]   Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes - A 6-month randomized placebo-controlled dose-response study [J].
Aronoff, S ;
Rosenblatt, S ;
Braithwaite, S ;
Egan, JW ;
Mathisen, AL ;
Schneider, RL .
DIABETES CARE, 2000, 23 (11) :1605-1611
[2]   Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARγ-modulating activity [J].
Benson, SC ;
Pershadsingh, HA ;
Ho, CI ;
Chittiboyina, A ;
Desai, P ;
Pravenec, M ;
Qi, NN ;
Wang, JM ;
Avery, MA ;
Kurtz, TW .
HYPERTENSION, 2004, 43 (05) :993-1002
[3]   The mechanisms of action of PPARs [J].
Berger, J ;
Moller, DE .
ANNUAL REVIEW OF MEDICINE, 2002, 53 :409-435
[4]   The role of the angiotensin system in cardiac glucose homeostasis - Therapeutic implications [J].
Bernobich, E ;
de Angelis, L ;
Lerin, C ;
Bellini, G .
DRUGS, 2002, 62 (09) :1295-1314
[5]   K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients [J].
Bolton, K ;
Beddhu, S ;
Campese, VM ;
Chavers, BM ;
Cheung, AK ;
Churchill, DN ;
Goldstein-Fuchs, J ;
Herzog, CA ;
Henrich, W ;
King, K ;
Kronenberg, F ;
Miholics, BS ;
Painter, PL ;
Parekh, R ;
Roberts, MS ;
Stehman-Breen, C ;
Stenvinkel, P ;
Wali, R ;
Weiss, MF .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2005, 45 (04) :S7-S153
[6]   BLOOD-PRESSURE-LOWERING BY PIOGLITAZONE - EVIDENCE FOR A DIRECT VASCULAR EFFECT [J].
BUCHANAN, TA ;
MEEHAN, WP ;
JENG, YY ;
YANG, D ;
CHAN, TM ;
NADLER, JL ;
SCOTT, S ;
RUDE, RK ;
HSUEH, WA .
JOURNAL OF CLINICAL INVESTIGATION, 1995, 96 (01) :354-360
[7]  
CRANBERRY MC, 1998, PHARMACOTHERAPY, V18, P973
[8]   Use of thiazolidinediones and risk of heart failure in people with type 2 diabetes - A retrospective cohort study [J].
Delea, TE ;
Edelsberg, JS ;
Hagiwara, M ;
Oster, G ;
Phillips, LS .
DIABETES CARE, 2003, 26 (11) :2983-2989
[9]   Further insight on the hypoglycemic and nonhypoglycemic effects of troglitazone 400 or 600 mg/d:: Effects on the very-low-density and high-density lipoprotein particle distribution [J].
Gómez-Pérez, FJ ;
Aguilar-Salinas, CA ;
Vázquez-Chávez, C ;
Fanghänel-Salmón, G ;
Gallegos-Martínez, J ;
Gómez-Díaz, RA ;
Salinas-Orozco, S ;
Chavira-López, IJ ;
Sánchez-Reyes, L ;
Torres-Acosta, EM ;
Tamez, R ;
López, A ;
Guillén, LE ;
Cesarman, G .
METABOLISM-CLINICAL AND EXPERIMENTAL, 2002, 51 (01) :44-51
[10]  
HAROLD JM, 2003, PHARMACOTHERAPY, V23, P861